Tetradecyltrimethylammonium bromide
产品说明书
 |
同义名 : | Tetradecyltrimethylammonium (bromide);TTAB;TTABr |
| CAS号 : | 1119-97-7 | |
| 货号 : | A289209 | |
| 分子式 : | C17H38BrN | |
| 纯度 : | 98% | |
| 分子量 : | 336.394 | |
| MDL号 : | MFCD00011770 | |
| 存储条件： |
Pure form Inert atmosphere,Room Temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
H2O: 120 mg/mL(356.72 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The endocytic protein dynamin II (dynII) is a 100-kDa GTPase enzyme best known for its participation in cell cycle progression and role in centrosome cohesion and cytokinesis. Myristyl trimethyl ammonium bromide (MitMAB) is a novel inhibitor of dynII GTPase activity with IC50 value of 8.4 ± 5.79 μM. It also inhibits dynI GTPase activity with IC50 value of 2.26 ± 0.53 μM. HeLa, H460, and SW480 cancer cells were treated with various concentrations of MitMAB for 7 d. Antiproliferative effect of MitMAB in these cells with a 50% reduction in colony formation was confiemed at concentration of ∼0.5 μM indicating MitMAB inhibited cell proliferation and reduce viability in a range of cancer cells. Asynchronously growing HeLa cells were treated for 48 h with MitMAB. Consistent with its effect on cell viability, it increased the sub-G1 (<2N DNA content) population, indicating apoptosis. G1 and S phase populations decreased, whereas the population of cells containing 4N DNA content (G2-M) increased. Therefore, MitMAB disrupted cell cycle progression and caused cytokinesis failure [1]. | ||
| 作用机制 | MitMAB inhibits dynamin GTPase activity by disrupting the PH (pleckstrin homology) domain-phospholipid interaction . | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.97mL 0.59mL 0.30mL |
14.86mL 2.97mL 1.49mL |
29.73mL 5.95mL 2.97mL |
| 参考文献 |
|---|